9-ethyl-N⁶-methyladenine | 21031-78-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 9-ethyl-N⁶-methyladenine
• 英文别名: 9-Ethyl-6-methylaminopurine；9-ethyl-N-methylpurin-6-amine
• CAS: 21031-78-7
• 化学式: C₈H₁₁N₅
• 分子量: 177.209
• InChiKey: KMWZZAYMCRKEEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  9-ethyl-N⁶-methyladenine 在 氘代甲醇 作用下， 以 氘代二甲亚砜 为溶剂， 生成 8-deuterio-9-ethyl-N⁶-methyladenine
  参考文献：
  名称：

  Maki, Yoshifumi; Kameyama, Keiji; Suzuki, Mikio, Journal of Chemical Research, Miniprint, 1984, # 12, p. 3601 - 3654

  摘要：

  DOI：
• 作为产物：
  描述：

  9-乙基-1-甲基腺嘌呤高氯酸盐 以 水 为溶剂， 生成 9-ethyl-N⁶-methyladenine
  参考文献：
  名称：

  Fujii, Tozo; Saito, Tohru, Chemical and pharmaceutical bulletin, 1985, vol. 33, # 9, p. 3635 - 3644

  摘要：

  DOI：

文献信息

• Reaction of 9-substituted adenines with chloroacetic anhydride. Formation of novel mesoionic imidazopyrines
  作者：Yoshifumi Maki、Mikio Suzuki、Munehiro Suzuki、Keiji Kameyama、Magoichi Sako

  DOI：10.1039/p19810003239

  日期：——

  Reaction of the 9-substituted adenines (1) with chloroacetic anhydride in boiling toluene has resulted in the formation of the novel mesoionic imidazopurines (3) in moderate to good yields. The reaction apparently involves an intramolecular alkylation of the initially formed 9-substituted N6-chloroacetyladenines (2) at N-1, which is in contrast with the exclusive N7-alkylation in the reaction of 9-substituted

  9-取代的腺嘌呤（1）与氯乙酸酐在沸腾的甲苯中的反应已导致以中等至良好的产率形成新型的中离子咪唑并嘌呤（3）。将反应显然涉及的分子内烷基化反应初始形成的9-取代的Ñ 6个在N-1，其与异对比度-chloroacetyladenines（2）ñ 7烷基化中的9-取代的反应Ñ 6个-acyladenines与烷基卤化物。
• Fujii, Tozo; Saito, Tohru, Chemical and pharmaceutical bulletin, 1985, vol. 33, # 9, p. 3635 - 3644
  作者：Fujii, Tozo、Saito, Tohru

  DOI：——

  日期：——
• INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA
  申请人：ICOS CORPORATION

  公开号：US20170049772A1

  公开（公告）日：2017-02-23

  Methods of inhibiting phosphotidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating disease, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity. Methods of using PI3Kδ inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3Kδ inhibitory compounds to inhibit PI3Kδ-mediated processes in vitro and in vivo.
• [EN] COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT<br/>[FR] COMBINAISONS D'ANTAGONISTES DE PD-1 ET D'AGONISTES DE STING DINUCLÉOTIDIQUES CYCLIQUES POUR LE TRAITEMENT DU CANCER
  申请人：MERCK SHARP & DOHME

  公开号：WO2018118664A1

  公开（公告）日：2018-06-28

  Therapeutic combinations that comprise at least one antagonist of the Programmed Death 1 receptor (PD-1) and at least one cyclic dinucleotide compound that activates the Stimulator of Interferon Genes (STING) pathway are disclosed herein. Also disclosed is the use of such therapeutic combinations for the treatment of cancers.
• Maki, Yoshifumi; Kameyama, Keiji; Suzuki, Mikio, Journal of Chemical Research, Miniprint, 1984, # 12, p. 3601 - 3654
  作者：Maki, Yoshifumi、Kameyama, Keiji、Suzuki, Mikio、Sako, Magoichi、Hirota, Kosaku

  DOI：——

  日期：——